Innovative first-in-class products comprise 30% of diabetes complications pipeline
![](/46/pdcnewsitem/04/14/79/GBI%20Research.png)
New targets need to be identified and converted into improved therapeutic options, particularly in order to develop therapies more aligned with the underlying disease pathophysiology, says GBI Research.
The diabetes complications space has high potential for changes and improvements as it becomes more diverse, with 30% of diabetic complication products in active development considered to be first-in-class, according to business intelligence provider GBI Research.
According to the company’s latest report — Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies — the market for diabetic complications is predominantly composed of therapies that symptomatically treat the condition and, at best, slow disease progression. However, as the understanding of disease pathophysiology increases, new targets need to be identified and converted into improved therapeutic options, particularly in order to develop therapies that are more aligned with the underlying disease pathophysiology.
Firas Nour, Associate Analyst for GBI Research, states that: “Although many first-in-class products fail to make an impact on the market even upon successful regulatory approval, higher-risk programs for innovative first-in-class products remain attractive and have led to some of the most clinically and commercially successful products of the past decade, including Avastin (bevacizumab) for diabetic macular edema and Rituxan (rituximab) for diabetic neuropathy.”
GBI Research has found that 31.7% of products in the entire metabolic pipeline are first-in-class, which means that diabetic neuropathies have a below-average proportion of first-in-class pipeline products. In the diabetic retinopathies segment, however, there is substantial innovation in the early pipeline, which offers signs that a greater proportion of first-in-class products will filter through to Phase III in the future.
Deal activity within the diabetic complications market varies with first-in-class status. Strategic consolidations have played an important role in developing therapeutics for diabetic complications in the past decade, with 81 licensing deals and 36 co-development deals having taken place since 2006.
Nour continues: “The deals in diabetic complications revealed that licensing deals did not reflect the industry-wide trend of first-in-class deals being more valuable. Co-development deals, meanwhile, were representative of the overall picture of the complications pipeline, reflecting the shift towards therapies that are more aligned with the underlying disease pathophysiology.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance